JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates lipid metabolism and attenuates atherosclerosis in hyperlipidemic animal models

Journal of Pharmacological Sciences

Volumn 129, Issue 3, 2015, Pages 169-176

  Mera, Yasuko ^a   Kawai, Takashi ^a   Ogawa, Naoto ^a   Odani, Naoya ^a   Sasase, Tomohiko ^a   Miyajima, Katsuhiro ^a   Ohta, Takeshi ^a   Kakutani, Makoto ^a  

^a JAPAN TOBACCO INC   (Japan)

Author keywords

Atherosclerosis; Dyslipidemia; HDL function; JTT 130; Microsomal triglyceride transfer protein

Indexed keywords

CHYLOMICRON; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; JTT 130; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CARRIER PROTEIN; DIETHYL 2-((3-DIMETHYLCARBAMOYL-4-((4'-TRIFLUOROMETHYLBIPHENYL-2-CARBONYL)AMINO)PHENYL)ACETYLOXYMETHYL)-2-PHENYLMALONATE; MALONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; FATTY LIVER; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; JAPANESE WHITE (RABBIT); LIPID ABSORPTION; LIPID LIVER LEVEL; LIPID METABOLISM; MACROPHAGE; MALE; NONHUMAN; SYRIAN HAMSTER; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; HAMSTER; HYPERLIPIDEMIAS; INTESTINE; LIPID DIET; MESOCRICETUS; METABOLISM; RABBIT;

ANIMALS; ATHEROSCLEROSIS; BENZAMIDES; CARRIER PROTEINS; CHOLESTEROL, HDL; CRICETINAE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HYPERLIPIDEMIAS; INTESTINES; LIPID METABOLISM; MALE; MALONATES; MESOCRICETUS; RABBITS;

EID: 84951291344     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1016/j.jphs.2015.10.004     Document Type: Article

References (32)

1. M. Merkler, and Z. Reiner The burden of hyperlipidaemia and diabetes in cardiovascular diseases Fundam Clin Pharmacol 21 Suppl. 2 2007 1 3
2. I. Graham, M.T. Cooney, D. Bradley, A. Dudina, and Z. Reiner Dyslipidemias in the prevention of cardiovascular disease: risks and causality Curr Cardiol Rep 14 2012 709 720
3. K. Matsumoto, T. Kobayashi, and Y. Kimura Isolation and preliminary characterization of antigenic variant of echovirus type 11 J Med Virol 31 1990 253 258
4. A. Sahebkar, and G.F. Watts New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes Clin Ther 35 2013 1082 1098
5. V.M. Alla, V. Agrawal, A. DeNazareth, S. Mohiuddin, S. Ravilla, and M. Rendell A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs Drugs 73 2013 1025 1054
6. C.J. Packard, and Y. Saito Non-HDL cholesterol as a measure of atherosclerotic risk J Atheroscler Thromb 11 2004 6 14
7. M. Miller, H.N. Ginsberg, and E.J. Schaefer Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease Am J Cardiol 101 2008 1003 1008
8. A. Sniderman, M. McQueen, J. Contois, K. Williams, and C.D. Furberg Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol 4 2010 152 155
9. E.M. deGoma, R.L. deGoma, and D.J. Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211
10. A. Rohatgi, A. Khera, J.D. Berry, E.G. Givens, C.R. Ayers, K.E. Wedin, and et al. HDL cholesterol efflux capacity and incident cardiovascular events N Engl J Med 371 2014 2383 2393
11. J.R. Wetterau, M.C. Lin, and H. Jamil Microsomal triglyceride transfer protein Biochim Biophys Acta 1345 1997 136 150
12. S.O. Olofsson, L. Asp, and J. Boren The assembly and secretion of apolipoprotein B-containing lipoproteins Curr Opin Lipidol 10 1999 341 346
13. D.A. Gordon, J.R. Wetterau, and R.E. Gregg Microsomal triglyceride transfer protein: a protein complex required for the assembly of lipoprotein particles Trends Cell Biol 5 1995 317 321
14. A.S. Wierzbicki, T. Hardman, and W.T. Prince Future challenges for microsomal transport protein inhibitors Curr Vasc Pharmacol 7 2009 277 286
15. Y. Mera, N. Odani, T. Kawai, T. Hata, M. Suzuki, A. Hagiwara, and et al. Pharmacological characterization of diethyl-2-({3-dimethylcarbamoyl-4-[(4'-trifluoromethylbiphenyl-2-carbonyl) amino]phenyl}acetyloxymethyl)-2-phenylmalonate (JTT-130), an intestine-specific inhibitor of microsomal triglyceride transfer protein J Pharmacol Exp Ther 336 2011 321 327
16. Y. Mera, T. Hata, Y. Ishii, D. Tomimoto, T. Kawai, T. Ohta, and et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, reduces food preference for fat J Diabetes Res 2014 2014 583752
17. T. Hata, Y. Mera, H. Tadaki, Y. Kuroki, T. Kawai, T. Ohta, and et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats Diabetes Obes Metab 13 2011 446 454
18. T. Hata, Y. Mera, T. Kawai, Y. Ishii, Y. Kuroki, K. Kakimoto, and et al. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, ameliorates impaired glucose and lipid metabolism in Zucker diabetic fatty rats Diabetes Obes Metab 13 2011 629 638
19. S.V. Hildebrand, and T. Hill 3rd Effects of atracurium administered by continuous intravenous infusion in halothane-anesthetized horses Am J Vet Res 50 1989 2124 2126
20. H. Okamoto, F. Yonemori, K. Wakitani, T. Minowa, K. Maeda, and H. Shinkai A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits Nature 406 2000 203 207
21. R.X. Zhao, W.J. Li, Y.R. Lu, J. Qin, C.L. Wu, M. Tian, and et al. Increased peripheral proinflammatory T helper subsets contribute to cardiovascular complications in diabetic patients Mediat Inflamm 2014 2014 596967
22. S.I. Chung, T.H. Kim, C.W. Rico, and M.Y. Kang Effect of instant cooked giant embryonic rice on body fat weight and plasma lipid profile in high fat-fed mice Nutrients 6 2014 2266 2278
23. M.M. Hussain, T.M. Leung, L. Zhou, and S. Abu-Merhi Regulating intestinal function to reduce atherogenic lipoproteins Clin Lipidol 8 2013
24. G. Rajagopal, V. Suresh, and A. Sachan High-density lipoprotein cholesterol: how High Indian J Endocrinol Metab 16 2012 S236 S238
25. A.R. Tall Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins J Intern Med 263 2008 256 273
26. A.V. Khera, M. Cuchel, M. de la Llera-Moya, A. Rodrigues, M.F. Burke, K. Jafri, and et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis N Engl J Med 364 2011 127 135
27. M. Shiomi, T. Koike, and T. Ito Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins Atherosclerosis 231 2013 39 47
28. H.R. Davis Jr., R.S. Lowe, and D.R. Neff Effects of ezetimibe on atherosclerosis in preclinical models Atherosclerosis 215 2011 266 278
29. P. Libby Inflammation in atherosclerosis Nature 420 2002 868 874
30. E.K. Koltsova, Z. Garcia, G. Chodaczek, M. Landau, S. McArdle, S.R. Scott, and et al. Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis J Clin Invest 122 2012 3114 3126
31. K.J. Moore, F.J. Sheedy, and E.A. Fisher Macrophages in atherosclerosis: a dynamic balance Nat Rev Immunol 13 2013 709 721
32. D. Ye, Y. Zhao, R.B. Hildebrand, R.R. Singaraja, M.R. Hayden, T.J. Van Berkel, and et al. The dynamics of macrophage infiltration into the arterial wall during atherosclerotic lesion development in low-density lipoprotein receptor knockout mice Am J Pathol 178 2011 413 422